# Interpace Biosciences Expects Q3 Revenue Growth Up to 14% Sequentially

- URL: https://stocks.freetheai.org/news/interpace-biosciences-expects-q3-revenue-growth-up-to-14-sequentially-e5aa96
- Published: 2026-10-15T00:29:00Z
- Category: earnings; sentiment: bullish; impact: medium
- Symbols: [OTC:IDXG](https://stocks.freetheai.org/symbols/OTC-IDXG)
- Written by our AI from expert market sources across the web for FreeTheAI Stocks, built by Vibhek Soni
- How write-ups are made: https://stocks.freetheai.org/how-we-write
- Not financial advice: https://stocks.freetheai.org/disclaimer

Interpace Biosciences, Inc. (IDXG) expects third-quarter 2026 revenue to fall between $10.1 million and $10.4 million. The preliminary, unaudited figures represent a sequential rise of approximately 11% to 14% compared to the second quarter of 2026, and a year-over-year increase of roughly 15% to 18% compared to the third quarter of 2025.

The quarter-over-quarter expansion points to renewed demand momentum for the company following a slower top-line performance during the first half of the year. Shares traded down 6.47% at $5.518 alongside the revenue disclosure.

Investors will look for finalized results, as the preliminary revenue estimate remains subject to quarter-end closing procedures and review. A complete picture of performance will depend on upcoming details regarding profit margins, cash flow, and potential updates to the full-year 2026 outlook.

## Key points

- Interpace Biosciences estimates preliminary Q3 2026 revenue between $10.1 million and $10.4 million.
- Projected revenue represents a sequential gain of 11% to 14% compared to Q2 2026.
- Compared to Q3 2025, revenue is expected to be up 15% to 18% year-over-year.
- The top-line growth marks an acceleration following a softer first half of 2026.

## Questions and answers

### What is Interpace Biosciences expected Q3 2026 revenue?

Interpace Biosciences expects preliminary Q3 2026 revenue to be between $10.1 million and $10.4 million, reflecting sequential growth of 11% to 14%.

### How much did Interpace Biosciences revenue grow year over year?

The company's projected third-quarter 2026 revenue represents an increase of approximately 15% to 18% compared to the third quarter of 2025.

### Are Interpace Biosciences Q3 2026 financial results finalized?

No, the figures are preliminary and unaudited, subject to standard quarter-end closing procedures and final review.